Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 3:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Healthy, Postmenopausal Women Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

IH636 Grape Seed Extract in Preventing Breast Cancer in Postmenopausal Women at Risk of Developing Breast Cancer

NCT00100893
View directory record Official record
Conditions
Breast Cancer
Interventions
IH636 grape seed proanthocyanidin extract
Dietary Supplement
Lead sponsor
City of Hope Medical Center
Other
Eligibility
40 Years to 75 Years · Female only
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Premarin and Bazedoxifene Potential Interaction

NCT00745173
View directory record Official record
Conditions
Postmenopause
Interventions
Premarin
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2009 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Oral Calcitonin Given at Night to Healthy Postmenopausal Women

NCT00803686
View directory record Official record
Conditions
Phase 1 Pharmacodynamic Study
Interventions
Oral rsCT tablet, Oral Placebo Tablet, Fortical (rsCT) nasal spray
Drug
Lead sponsor
Tarsa Therapeutics, Inc.
Industry
Eligibility
45 Years to 70 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Calcium Retention as Influenced by Dietary Components That Induce an Acid Load

NCT00620763
View directory record Official record
Conditions
Healthy
Interventions
High Meat - High Potential Renal Acid Load (PRAL) diet, Low Protein - Low Potential Renal Acid Load (PRAL) diet
Other
Lead sponsor
USDA Grand Forks Human Nutrition Research Center
Federal
Eligibility
40 Years to 75 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2541546 in Healthy Postmenopausal Women

NCT01742078
View directory record Official record
Conditions
Healthy
Interventions
LY2541546 - IV, LY2541546 - SC, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years to 70 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
Evansville, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Early Menopause Hormone Treatment and Cognition

NCT01046643
View directory record Official record
Conditions
Menopausal Syndrome
Interventions
Estradiol (E2), Progesterone (P10) x90, Progesterone (P10) x10
Drug
Lead sponsor
University of Michigan
Other
Eligibility
45 Years to 55 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 18, 2014 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Aspirin on Mammogram Density in Healthy Postmenopausal Women With a Moderate or High Level of Breast Density

NCT00470561
View directory record Official record
Conditions
Mammographic Breast Density
Interventions
Aspirin, Placebo
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
55 Years to 75 Years · Female only
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 14, 2010 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women

NCT01829919
View directory record Official record
Conditions
Postmenopausal Symptoms
Interventions
Brisdelle (paroxetine mesylate)
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
40 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Adhesion Quality of a New Formulation of the Mylan Estradiol Transdermal System 0.025 mg/Day and Climara® Transdermal System 0.025 mg/Day

NCT00649896
View directory record Official record
Conditions
Healthy
Interventions
Mylan Estradiol Transdermal System 0.025 mg/day, Climara® Transdermal System 0.025 mg/day
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
40 Years to 69 Years · Female only
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2008 · Synced Sep 23, 2026, 3:58 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women

NCT01634789
View directory record Official record
Conditions
Healthy
Interventions
bazedoxifene, bazedoxifene/conjugated estrogens
Drug
Lead sponsor
Pfizer
Industry
Eligibility
45 Years to 64 Years · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling

NCT01438073
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism, Healthy Postmenopausal Women, Agonadism
Interventions
kisspeptin 112-121, GnRH
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2022 · Synced Sep 23, 2026, 3:58 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Time Restricted Diet in Obese or Overweight Pre or Postmenopausal Participants

NCT02154984
View directory record Official record
Conditions
Healthy, no Evidence of Disease, Obesity
Interventions
behavioral dietary intervention, telephone-based intervention, laboratory biomarker analysis
Behavioral · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 30, 2020 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women

NCT02364882
View directory record Official record
Conditions
Female Sexual Health
Interventions
Sildenafil
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 21, 2015 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Comparing Premarin®/MPA, PREMPRO® and Provera® in Healthy Postmenopausal Women

NCT00543634
View directory record Official record
Conditions
Postmenopause
Interventions
Premarin/MPA, Provera 10 mg
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 21, 2010 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder

NCT02101203
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Placebo, 0.5 mgTestosterone + 10 mg Buspirone
Drug
Lead sponsor
Emotional Brain NY Inc.
Industry
Eligibility
21 Years to 70 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
10
States / cities
San Diego, California • Bradenton, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women

NCT06908707
View directory record Official record
Conditions
Postmenopausal, Healthy Adult Female Participants
Interventions
LAE102 SC, Placebo SC, LAE102 IV, Placebo IV
Drug
Lead sponsor
Laekna Limited
Industry
Eligibility
45 Years to 75 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Hepatic Impairment on LDE225..

NCT01764776
View directory record Official record
Conditions
Normal Hepatic Function, Impaired Hepatic Function
Interventions
LDE225
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg

NCT00648154
View directory record Official record
Conditions
Healthy
Interventions
Letrozole Tablets 2.5 mg, Femara® Tablets 2.5 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
40 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 30, 2009 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect Study of D-0502 Tablet in Healthy Volunteers

NCT03810625
View directory record Official record
Conditions
Breast Cancer
Interventions
D-0502
Drug
Lead sponsor
InventisBio Co., Ltd
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Study of ACE-083 in Healthy Subjects

NCT02257489
View directory record Official record
Conditions
Musculoskeletal Diseases
Interventions
ACE-083
Drug
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
45 Years to 75 Years · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Genistein in Preventing Breast or Endometrial Cancer in Healthy Postmenopausal Women

NCT00099008
View directory record Official record
Conditions
Breast Cancer, Endometrial Cancer
Interventions
Genistein, Placebo
Dietary Supplement
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0980 Following Single Oral Dose Administration in Healthy Postmenopausal Female Subjects

NCT01487239
View directory record Official record
Conditions
Healthy Volunteer
Interventions
[14C]-GDC-0980
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate The Metabolism And Excretion Of 14C SB-751689 Given To Healthy Males And Postmenopausal Women

NCT00499928
View directory record Official record
Conditions
Osteoporosis
Interventions
SB-751689
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
35 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 17, 2009 · Synced Sep 23, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Resveratrol in Postmenopausal Women With High Body Mass Index

NCT01370889
View directory record Official record
Conditions
Healthy, no Evidence of Disease
Interventions
resveratrol, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
35 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Sep 23, 2026, 3:58 PM EDT